Hemispherx Biopharma, Inc HEB:AMEX
Education help is ON
Sector: Healthcare Industry: Biotechnology & Drugs
1.02 Arrow Down-0.01   -0.97% 1,097,632 Market data is delayed by at least 20 minutes.
Last Change  /  % Change Volume
Exclusive
Features
 
When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes. Or
 
1day |  5day |  6mo |  1yr |  5yr

Latest News Headlines for Hemispherx Biopharma, Inc

Friday 11/20/2009 6:00 PM ET - GlobeNewswire

The Brualdi Law Firm, P.C. announces that a lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (AMEX:HEB) stock during the period between February 18, 2009 and October 30, 2009, inclusive (the "Class Period") for violations of the federal securities laws.

Tuesday 11/17/2009 10:29 AM ET - Comtex SmarTrend(R)

SmarTrend, our proprietary pattern recognition system, called a Downtrend for Hemispherx Biopharma (AMEX:HEB) on August 03, 2009 at $2.13.

Since then, Hemispherx Biopharma has returned 50.1% as of today's recent price of $1.06. Want to profit from these alerts?

Monday 11/16/2009 8:45 AM ET - GlobeNewswire

Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") said the recently filed lawsuit is without merit. The lawsuit is based upon the false claim that "...defendants failed to disclose that the FDA had requested several reports from the Company before the NDA could even be considered..." regarding the Ampligen(R) (Poly I : Poly C12U) investigational product. That claim is irrefutably false.

Saturday 11/14/2009 9:12 AM ET - Market Wire

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of the securities of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (AMEX: HEB) during the period between February 18, 2009 and October 30, 2009, inclusive (the "Class Period").

Thursday 11/12/2009 4:38 PM ET - Market Wire

The law firm of Izard Nobel LLP, which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of those who purchased the securities of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (AMEX: HEB) between February 18, 2009 and October 30, 2009 (the "Class Period").

Earlier Headlines - view recent headlines
--/--

Bid/Size

--/--

Ask/Size

1.01

Price Open

1.03

Previous Close

1.03

Day High

0.98

Day Low

0.90

Beta (5yr)

4.54/6/5/09

52wk High/Date

0.26/2/18/09

52wk Low/Date

135.4 Million

Market Capitalization

132.7 Million

Shares Outstanding

182.37

Volatility Avg (1 Year)

2.2 Million

Avg Vol (10 day)

NM

P/E Ratio

-0.1594

EPS (TTM)

Hemispherx Biopharma, Inc does not pay dividends.

Scottrade Customers

Get the following exclusive content at no additional cost with your Scottrade account:

  • Standard & Poor's STARS Rating for the featured stock
  • Research reports from Reuters and Standard & Poor's
  • Market Edge Second Opinion Weekly Report

For full analysis, Open an Account or Log In with Scottrade

Hemispherx Biopharma, Inc vs. Peers

Company Market Cap YTD Price Performance
HEB

Hemispherx Biopharma, Inc

128.8M
+183.3%
PFE

Pfizer Inc.

148.2B
+3.7%
MRK

Merck & Co., Inc.

111.4B
+19.9%
GILD

Gilead Sciences, Inc.

41.7B
-9.3%
AVII

AVI BioPharma, Inc.

125.2M
+121.9%

Company Background

Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen and Alferon N and Injection. Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer(adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.

© 2008 Scottrade

Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC

Online market and limit stock trades are just $7 for stocks priced $1 and above.

Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or None of the information provided should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.

Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade branch office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.

Investors should consider the investment objectives, charges, expense, and unique risk profile of an Exchange Traded Fund (ETF) carefully before investing. Leveraged and Inverse ETFs may not be suitable for long-term investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. A prospectus contains this and other information about the ETF and should be obtained from the issuer. The prospectus should be read carefully before investing.

Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.

Options involve risk and are not appropriate for all investors. Detailed information about the risks associated with options can be found in the Scottrade Options Application and Agreement, Brokerage Account Agreement, or by downloading the Characteristics and Risks of Standardized Options and Supplements (PDF) from The Options Clearing Corporation, or by requesting a copy from your local branch office. Supporting documentation for any claims will be supplied upon request.

Market volatility, volume, and system availability may impact account access and trade execution.

Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.